ADARx Pharmaceuticals, Inc.
ADRXHealthcare|Biotechnology|US
$13.23
-0.06 (-0.45%)
About
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
Stock Price
-31.6%(1Y)
1M
-25.2%
3M
-31.6%
6M
-31.6%
YTD
-31.6%
1Y
-31.6%
3Y
-31.6%
5Y
-31.6%
Pipeline Summary
9 total trials4
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
Active: 2Recruiting: 7
Active Trials (9)
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
NCT06205628Hypertension
Phase 1Active
Enrollment: 28 participants
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1Phase 2Recruiting
Enrollment: 50 participants
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
NCT05691361Hereditary Angioedema
Phase 1Phase 2Active
Enrollment: 53 participants
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN)
Phase 2Recruiting
Enrollment: 30 participants
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase 2Recruiting
Enrollment: 240 participants
Key Facts
Market Cap$1.47B
Employees100
CEOZhen Li
IPO DateSep 25, 2026
Beta0.00
52-Week Range$12.5 – $23.21
Avg Volume666,254
ExchangeNASDAQ
Websiteadarx.com
Ownership
Float16.9%
Shares Outstanding110.7M
Recent Insider Trades
RICE THOMAS PDISPOSED
Nov 3, 2006112,619 shares @ $25.00
RICE THOMAS PDISPOSED
Nov 3, 200615,000 shares @ $11.45
RICE THOMAS PDISPOSED
Nov 3, 2006150,000 shares @ $29.96
WATKINS IAN JDISPOSED
Nov 3, 200630,000 shares @ $8.85
WATKINS IAN JDISPOSED
Nov 3, 200630,000 shares @ $25.64
Peers
Recent News
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Oct 1, 2026 · globenewswire.com
First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks
Sep 30, 2026 · gurufocus.com
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
Sep 25, 2026 · reuters.com
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
Sep 24, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:52 AM